MetaVia announces Phase 1 data: DA-1726 48 mg yields 9.1% weight loss at Day 54 without plateau

MetaVia Inc.

48 mg cohort achieved 9.1% mean body weight reduction at Day 54; no plateau through Week 8.
Exploratory FibroScan showed liver improvements: CAP -20.0 dB/m vs +24.0 placebo; liver stiffness -10.3% vs +13.8%.
No serious adverse events or treatment-related discontinuations; GI events mild-to-moderate and transient.
Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo at Day 26).
Ongoing Phase 1 Part 3a/3b titration studies evaluate extended treatment at higher doses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.